Last reviewed · How we verify
Samia Hassan El-Shishtawy — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Astrazenica vaccine | Astrazenica vaccine | phase 3 | Viral vector vaccine | SARS-CoV-2 spike protein | Immunology / Infectious Disease |
Therapeutic area mix
- Immunology / Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Aeras · 1 shared drug class
- Bharat Biotech International Limited · 1 shared drug class
- CanSino Biologics Inc. · 1 shared drug class
- Cellid Co., Ltd. · 1 shared drug class
- Crucell Holland BV · 1 shared drug class
- D'Or Institute for Research and Education · 1 shared drug class
- EuBiologics Co.,Ltd · 1 shared drug class
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Samia Hassan El-Shishtawy:
- Samia Hassan El-Shishtawy pipeline updates — RSS
- Samia Hassan El-Shishtawy pipeline updates — Atom
- Samia Hassan El-Shishtawy pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Samia Hassan El-Shishtawy — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/samia-hassan-el-shishtawy. Accessed 2026-05-17.